fda glp-1 compounding enforcement news FDA proposes a new GLP-1 compounding crackdown

FDA is moving to restrict mass-marketed compounded GLP-1 products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger enforcement to protect patients from unverified

29.00

★★★★☆4.8 (126)

Report: FDA must enforce rules on compounded GLP-1s

25.33

★★★★★4.9 (98)

🚨 Regulatory tightening is expanding beyond cannabinoids. With the FDA officially ending the GLP-1 shortage designation, the compounding loophole for certain peptide medications is closing triggering patent enforcement, compliance scrutiny, and market

28.16

★★★★★5.0 (157)

FDA is moving to restrict mass-marketed compounded GLP-1 products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger enforcement to protect patients from unverified

25.55

★★★★★4.7 (84)

September 15, 2025: Telehealth company must stop implying its compounded GLP -1 is FDA-approved, warns FDA – Partnership for Safe Medicines

29.96

★★★★★4.9 (203)

The FDA recently published updates clarifying policies for compounding drug manufacturers producing GLP-1 medications post drug shortage. In this post, Dr. Brian LaMar explains what those updated guidelines mean, why Parkview Weight

28.10

★★★★★5.0 (176)

GLP-1 compounding is facing increased scrutiny, and the path forward is far from clear. ㅤ Recent FDA messaging has raised questions across the industry, with potential enforcement around GLP-1 APIs creating uncertainty

23.84

★★★★★4.8 (132)